Quick Answer
ImmunityBio, Inc. reported Stockholders Equity of -$500.47 million for fiscal year 2025.
ImmunityBio, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$500.47M | -2.3% |
| 2024 | -$489.10M | +16.7% |
| 2023 | -$586.99M | -31.2% |
| 2022 | -$447.33M | -84.7% |
| 2021 | -$242.17M | -102.1% |
| 2020 | -$119.81M | -199.3% |
| 2019 | $120.68M | -17.3% |
| 2018 | $146.01M | -33.3% |
| 2017 | $218.84M | -25.4% |
| 2016 | $293.42M | -17.6% |
| 2015 | $356.00M | +518.1% |
| 2014 | $57.59M | +1633.7% |
| 2013 | -$3.75M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$524.32M | +29.6% | +8.1% |
| June 30, 2025 | -$570.75M | +18.3% | +3.5% |
| March 31, 2025 | -$591.43M | +14.5% | -20.9% |
| December 31, 2024 | -$489.10M | +16.7% | +34.4% |
| September 30, 2024 | -$745.15M | -81.0% | -6.7% |
| June 30, 2024 | -$698.39M | -8.8% | -0.9% |
| March 31, 2024 | -$692.01M | -30.8% | -17.9% |
| December 31, 2023 | -$586.99M | -31.2% | -42.6% |
- ImmunityBio, Inc. showed a decrease of -2.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, ImmunityBio, Inc.’s stockholders equity has declined by 13228.1% (from -$3.75 million to -$500.47 million).
- The most recent figure is from ImmunityBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: